Item 9A. Controls and Procedures
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2024. Pursuant to Rule13a−15(e) promulgated by the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), “disclosure controls and procedures” means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the Commission is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms. “Disclosure controls and procedures” include, without limitation, controls and procedures designed to ensure that information that we are required to disclose in the reports we file with the Commission is accumulated and communicated to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure.
Based on their evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2024.
This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permits the Company to provide only management's report in this annual report.
Management Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15d-(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting include those policies and procedures that:
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.
Our management, including the undersigned principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In conducting its assessment, our management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework in 2013 . Based on this assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
83
Table of Contents
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act, that occurred during the fourth fiscal quarter of 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Disclosure Controls and Procedures
The effectiveness of our disclosure controls and procedures is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of our systems, the possibility of human error, and the risk of fraud. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions and the risk that the degree of compliance with policies or procedures may deteriorate over time. Because of these limitations, there can be no assurance that any system of disclosure controls and procedures, no matter how well conceived, will be successful in preventing all errors or fraud or in making all material information known in a timely manner to the appropriate levels of management.
Inherent Limitations on Internal Control
Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations, including the possibility of human error and circumvention by collusion or overriding of control. Accordingly, even an effective internal control system may not prevent or detect material misstatements on a timely basis. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that the controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, our internal control over financial reporting is designed to provide reasonable assurance of achieving their objectives.
Item 9B. Other Information
During the quarter ended December 31, 2024, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Regulation S-K Item 408 .
Item 9C. Disclosures regarding Foreign Jurisdictions that Prevent Inspections
Not Applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Information required by this item will be contained in the Proxy Statement as follows:
• The information relating to our executive officers is to be included in the section entitled “Information about our Executive Officers,”
• The information relating to our directors and nominees for director is to be included in the section entitled “Election of Directors” and “Information Regarding the Board of Directors and Corporate Governance,”
• The information relating to our audit committee and audit committee financial expert is to be included in the section “Information Regarding the Board of Directors and Corporate Governance,” and
• The information relating to our insider trading policies and procedures required by Item 408(b) of Regulation S-K is to be included in the section “Our Insider Trading Policy”, and
• If required, the information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled “Delinquent Section 16(a) Reports.”
Such information will be included in the Proxy Statement and is incorporated herein by reference.
84
Table of Contents
We have adopted a written Code of Business Conduct and Ethics (Code of Conduct) that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Conduct is available on our website at www.chromadex.com. If we make any substantive amendments to the Code of Conduct or grant any waiver from a provision of the Code of Conduct to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website in lieu of filing such waiver or amendment in a Current Report on Form 8-K.
Item 11. Executive Compensation
Information required by this item will be contained in the Proxy Statement under the caption “Executive Officers and Management Compensation” and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Information required by this item will be contained in the Proxy Statement under the caption “Security Ownership of Certain Beneficial Owners and Management” and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
Information required by this item will be contained in the Proxy Statement under the caption “Certain Relationships and Related Transactions” and “Information Regarding the Board of Directors and Corporate Governance” and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
Marcum LLP served as our independent registered public accounting firm from January 1, 2024 to October 31, 2024. Effective December 13, 2024, Crowe LLP, Audit Firm ID: 173, is our independent registered public accounting firm.
The information required by this item is to be included in our Proxy Statement under the caption “Ratification of the Appointment of Independent Registered Public Accounting Firm” and is incorporated herein by reference.
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
Reference is made to Item 8 of this Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules
All schedules have been omitted because they are not required or because the required information is given in the Financial Statements or Notes thereto set forth under Part II, Item 8 of this Annual Report on Form 10-K.
(a)(3) List of Exhibits
INDEX TO EXHIBITS
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
2.1 Agreement and Plan of Merger, dated as of May 21, 2008, among Cody, CDI Acquisition, Inc. and ChromaDex, Inc. as amended on June 10, 2008
8-K 333-140056 2.1 6/24/2008
3.1 Amended and Restated Certificate of Incorporation of the Registrant
10-K 001-37752 3.1 3/15/2018
3.2 Certificate of Amendment to the Certificate of Incorporation of the Registrant
8-K 001-37752 3.1 4/12/2016
85
Table of Contents
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
3.3 Amended and Restated Bylaws of the Registrant
8-K 001-37752 3.1 3/17/2023
4.1 Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of December 10, 2018
10-K 001-37752 4.5 3/7/2019
4.2 Description of Common Stock of the Registrant
10-K 001-37752 4.6 3/10/2020
4.3 Registration Rights Agreement, dated as of May 9, 2019, by and among the Registrant and the parties thereto
8-K 001-37752 99.2 5/10/2019
4.4 Registration Rights Agreement, dated as of August 15, 2019, by and among the Registrant and the parties thereto
8-K 001-37752 99.1 8/15/2019
4.5 Registration Rights Agreement, dated as of April 27, 2020, by and among the Registrant and the parties thereto
8-K 001-37752 99.2 4/29/2020
4.6 Registration Rights Agreement, dated as of September 30, 2022, by and among the Registrant and the parties thereto
8-K 001-37752 10.3 10/3/2022
10.1 Second Amended and Restated 2007 Equity Incentive Plan effective March 13, 2007, as amended May 20, 2010 (1)+
DEF 14A 000-53290 Appendix B 5/4/2010
10.2 Form of Stock Option Agreement under the ChromaDex, Inc. Second Amended and Restated 2007 Equity Incentive Plan(1)+
8-K 333-140056 10.3 6/24/2008
10.3 Form of Restricted Stock Purchase Agreement under the ChromaDex, Inc. 2007 Equity Incentive Plan(1)+
8-K 333-140056 10.4 6/24/2008
10.4 ChromaDex Corporation 2017 Equity Incentive Plan, as amended +
8-K 001-37752 10.1 6/20/2023
10.5 Amended and Restated Employment Agreement dated April 19, 2010, by and between Frank L. Jaksch, Jr. and ChromaDex, Inc. (1)+
8-K 000-53290 10.1 4/22/2010
10.6 Amendment, dated June 22, 2018, to the Amended and Restated Employment Agreement, by and between Frank L. Jaksch Jr. and ChromaDex, Inc. +
8-K 001-37752 10.2 6/28/2018
10.7 Waiver of bonus compensation agreement dated February 13, 2023, by and between Frank L. Jaksch Jr. and ChromaDex, Inc. +
10-K 001-37752 10.6 3/8/2023
10.8 Restated and Amended License Agreement, effective as of June 3, 2015 between the University of Mississippi and ChromaDex, Inc.*
10-Q 000-53290 10.2 8/13/2015
10.9 License Agreement, effective as of October 15, 2014 between University of Mississippi and ChromaDex, Inc.*
10-K 000-53290 10.40 3/19/2015
10.10 First Amendment to Exclusive License Agreement, effective as of July 6, 2015, between University of Mississippi and ChromaDex, Inc.
10-Q 001-37752 10.7 11/10/2016
10.11 Lease Agreement, made as of April 14, 2016, by and between Longmont Diagonal Investments LLC and ChromaDex Analytics, Inc.
8-K 000-53290 10.1 4/20/2016
10.12 First Amendment to Lease Agreement, dated August 3, 2020, by and between ChromaDex Analytics, Inc. and 62 1625-1751 S. Fordham LLC and 64 1625-1751 S. Fordham LLC
10-Q 001-37752 10.8 11/4/2020
10.13 Form of Indemnity Agreement, between the Registrant and each of its existing directors and executive officers +
8-K 001-37752 10.1 12/16/2016
10.14 Amended and Restated Non-Employee Director Compensation Policy +
10-Q 001-37752 10.4 8/9/2018
86
Table of Contents
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
10.15 Form of Restricted Stock Award Agreement for Robert Fried +
10-Q 001-37752 10.3 5/11/2017
10.16 Amended and Restated Executive Employment Agreement, dated June 22, 2018, by and between Robert Fried and the Registrant +
8-K 001-37752 10.1 6/28/2018
10.17 Amendment to Amended and Restated Executive Employment Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant
8-K 001-37752 10.1 2/27/2025
10.18 Performance Stock Unit Award Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant
8-K 001-37752 10.2 2/27/2025
10.19 Lease, dated July 6, 2017, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-K 001-37752 10.50 3/7/2019
10.20 First Amendment to Lease, dated February 7, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-K 001-37752 10.51 3/7/2019
10.21 Second Amendment to Lease, dated June 30, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-K 001-37752 10.52 3/7/2019
10.22 Third Amendment to Lease, dated November 9, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-K 001-37752 10.53 3/7/2019
10.23 Fourth Amendment to Lease, dated December 20, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-K 001-37752 10.24 3/6/2024
10.24 Fifth Amendment to Lease, dated May 21, 2021, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-Q 001-37752 10.1 8/3/2021
10.25
Sixth Amendment to Lease, dated October 11, 2023, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.
10-Q 001-37752 10.1 11/8/2023
10.26 Securities Purchase Agreement dated April 26, 2017, by and among the Company and the Purchasers
8-K 001-37752 99.1 4/27/2017
10.27 Amended and Restated Supply Agreement, dated October 10, 2022, by and between the Company, Nestec Ltd. and NHSc **
10-Q 001-37752 10.6 11/2/2022
10.28 First Amendment to the Amended and Restated Supply Agreement, dated August 16, 2023, by and between the Company, Nestec Ltd. and NHSc **
10-Q 001-37752 10.2 11/8/2023
10.29 At Market Issuance Sales Agreement, dated as of June 12, 2020, by and among ChromaDex Corporation, B. Riley FBR, Inc. and Raymond James & Associates, Inc.
S-3 333-237144 1.2 6/12/2020
10.30 Amendment No. 1, dated November 20, 2024, to the At Market Issuance Sale Agreement, dated June 12, 2020
8-K 001-37752 1.1 11/21/2024
10.31 Business Financing Agreement, dated November 12, 2019, by and between ChromaDex Corporation and Western Alliance Bank
10-K 001-37752 10.45 3/10/2020
10.32 First Modification to Business Financing Agreement dated October 7, 2020, by and between ChromaDex Corporation and Western Alliance Bank
10-K 001-37752 10.43 3/12/2021
10.33 Second Modification to Business Financing Agreement dated November 10, 2021, by and between ChromaDex Corporation and Western Alliance Bank
10-K 001-37752 10.42 3/14/2022
87
Table of Contents
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
10.34 Consent to Business Financing Agreement, dated January 14, 2021, by and among Western Alliance Bank and ChromaDex Corporation
10-Q 001-37752 10.4 5/6/2021
10.35 Third Modification to Business Financing Agreement dated December 11, 2021 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex, Inc. and ChromaDex Analytics, Inc.
8-K 001-37752 10.1 12/14/2021
10.36 Fourth Modification to Business Financing Agreement dated November 9, 2023 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.
8-K 001-37752 10.1 12/13/2023
10.37 Fifth Modification to Business Financing Agreement dated December 8, 2023 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.
8-K 001-37752 10.2 12/13/2023
10.38 Sixth Modification to Business Financing Agreement dated November 18 , 202 4 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.
X
10.39 Manufacturing and Supply Agreement, dated as of January 1, 2016, by and between ChromaDex, Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.1 11/4/2020
10.40 First Amendment to Manufacturing and Supply Agreement, dated as of February 27, 2017, by and between ChromaDex, Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.2 11/4/2020
10.41 Second Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2018, by and between ChromaDex, Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.3 11/4/2020
10.42 Third Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2019, by and between ChromaDex, Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.4 11/4/2020
10.43 Fourth Amendment to Manufacturing and Supply Agreement, dated as of April 15, 2019, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.5 11/4/2020
10.44 Fifth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2020, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.6 11/4/2020
10.45 Sixth Amendment to Manufacturing and Supply Agreement, dated as of September 17, 2020, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.7 11/4/2020
10.46 Seventh Amendment to Manufacturing and Supply Agreement, dated as of August 2, 2021, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. **
10-Q 001-37752 10.3 8/3/2021
10.47 Eighth Amendment to Manufacturing and Supply Agreement, dated as of December 14, 2022, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**
10-K 001-37752 10.50 3/8/2023
10.48 Ninth Amendment to Manufacturing and Supply Agreement, dated as of November 2, 2023, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**
10-Q 001-37752 10.3 11/8/2023
88
Table of Contents
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
10.49 Tenth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2025, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**
10-Q 001-37752 10.2 10/31/2024
10.50 Exclusive License Agreement, dated September 8, 2011, by and between ChromaDex, Inc. and The Regents of the University of California **
10-Q 001-37752 10.1 11/3/2021
10.51 Lease, dated November 24, 2021, by and between Flight Phase I Owner, LLC and ChromaDex Corporation
10-K 001-37752 10.59 3/14/2022
10.52 First Amendment to the Joint Ownership Management Agreement, effective March 9, 2022, between Queen’s University of Belfast and ChromaDex, Inc.
10-Q 001-37752 10.5 5/12/2022
10.53 Joint Ownership Management Agreement, effective October 9, 2015, between Queen’s University of Belfast and ChromaDex, Inc.
10-Q 001-37752 10.6 5/12/2022
10.54 Securities Purchase Agreement, dated September 30, 2022, by and among the Company and the Purchasers
8-K 001-37752 10.2 10/3/2022
10.55 Securities Purchase Agreement, dated as of October 10, 2022, by and between the Company and the Purchaser *
8-K 001-37752 10.1 10/11/2022
10.56 Executive Employment Agreement, dated January 1, 2023, by and between Brianna Gerber and the Registrant +
8-K 001-37752 10.1 1/5/2023
10.57 Letter Agreement and Consulting Agreement, dated as of June 25, 2024, by and between the Company and Brianna Gerber
8-K 001-37752 10.1 6/25/2024
10.58 Amended and Restated Incentive Compensation Recoupment Policy +
10-K 001-37752 10.60 3/6/2024
10.59 Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc. +
8-K 001-37752 10.1 9/20/2024
10.60 Offer Letter, dated June 27, 2024, by and between Carlos Lopez and ChromaDex, Inc. +
X
16.1 Letter from Marcum LLP, dated as of October 11, 2024, addressed to the Securities and Exchange Commission
8-K 001-37752 16.1 10/11/2024
19.1 Insider Trading Policy
X
21.1
Subsidiaries of ChromaDex Corporation
X
23.1
Consent of Crowe, LLP, Independent Registered Public Accounting Firm
X
23.2 Consent of Marcum, LLP, Independent Registered Public Accounting Firm
24.1 Power of Attorney (included on the signature page of this Annual Report on Form 10-K) X
31.1
Certification of the Chief Executive Officer pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended
X
31.2
Certification of the Chief Financial Officer pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended
X
32.1
Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)
X
97.1 Dodd-Frank Clawback Policy +
10-K 001-37752 97.1 3/6/2024
89
Table of Contents
Incorporated by Reference Filed or
Furnished
Herewith
Exhibit No. Description Form File Number Exhibit Filing Date
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File - formatted in Inline XBRL and included in Exhibit 101
(1) Plan and related Forms were assumed by ChromaDex Corporation pursuant to Agreement and Plan of Merger, dated as of May 21, 2008, among ChromaDex Corporation (formerly Cody Resources, Inc.), CDI Acquisition, Inc. and ChromaDex, Inc.
(2) Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. ChromaDex Corporation undertakes to furnish supplemental copies of any of the omitted schedules upon request by the Securities and Exchange Commission; provided, however, that ChromaDex Corporation may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule so furnished.
+ Indicates management contract or compensatory plan or arrangement.
* This Exhibit has been granted confidential treatment and has been filed separately with the Commission. The confidential portions of this Exhibit have been omitted and are marked by an asterisk.
** Certain portions of this exhibit are omitted because they are both not material and are the type that the Registrant treats as private or confidential.
Item 16. Form 10-K Summary
None.
90
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CHROMADEX CORPORATION
By: /s/ ROBERT FRIED
Robert Fried
Chief Executive Officer
Date: March 4, 2025
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Fried and Ozan Pamir, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
Signature Title Date
/s/ ROBERT FRIED Chief Executive Officer and Director March 4, 2025
Robert Fried (Principal Executive Officer)
/s/ OZAN PAMIR Chief Financial Officer March 4, 2025
Ozan Pamir (Principal Financial and Accounting Officer)
/s/ FRANK JAKSCH JR. Chairman of the Board and Director March 4, 2025
Frank Jaksch Jr.
/s/ STEVEN RUBIN Director March 4, 2025
Steven Rubin
/s/ WENDY YU Director March 4, 2025
Wendy Yu
/s/ GARY NG Director March 4, 2025
Gary Ng
/s/ ANN COHEN Director March 4, 2025
Ann Cohen
/s/ KRISTIN PATRICK Director March 4, 2025
Kristin Patrick
/s/ HAMED SHAHBAZI Director March 4, 2025
Hamed Shahbazi
91